CD8A and neoplasm: For this reason, PD-1 has been proposed as the marker that more comprehensively identifies the repertoire of tumour-specific TILs.11 Recently, we have shown that the enrichment and separate amplification of PD-1+ CD8 TILs improves the antitumour efficacy of TIL therapy in mouse models of solid tumours.13 Our results were further confirmed by Jing et al. in haematological tumours.14